Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05403528
Other study ID # AS-18-155
Secondary ID R15HD101841
Status Withdrawn
Phase N/A
First received
Last updated
Start date April 7, 2022
Est. completion date April 2024

Study information

Verified date October 2023
Source Oklahoma State University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this work is to address increasing concerns about young children's digital media exposure and language outcomes by testing how the times course of word learning unfolds in digital environments and the cascading impact of digital media on vocabulary outcomes. The findings will have important implications for understanding when and where optimal word learning from media can occur.


Description:

The goal of the current proposal is to identify how digital media alters the mechanisms of word learning and subsequently impacts the lexical foundation on which a child's vocabulary is built. Specifically, the proposal aims to identify the impact of digital media on 1) the processes underlying real-time word learning, and 2) the processes of language generalization and vocabulary growth. Specific Aim 1 will use a novel word learning task to test children's ability to map and retain new words within and between digital media (2D images on a tablet) and real world objects (3D objects). Specific Aim 2 will probe children's novel label generalization abilities within and between 2D and 3D modalities using a novel noun generalization task. Further, individual differences in a child's prior technology experience will be measured and used to predict overall vocabulary as well as performance within and between each task.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2024
Est. primary completion date December 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 17 Months to 30 Months
Eligibility Inclusion Criteria: - between 17-30 months old Exclusion Criteria: - diagnosed developmental delay or disorder - exposure to more than 25% of another language

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Modality - 3D-2D
Modality in which items will be presented (via tablet/digital media or as real object). 3D items initially and retention/generalization as 2D
Modality - 2D-3D
Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 3D
Modality - 2D-2D
Modality in which items will be presented (via tablet/digital media or as real object). 2D items initially and retention/generalization as 2D

Locations

Country Name City State
United States Oklahoma State University Stillwater Oklahoma

Sponsors (2)

Lead Sponsor Collaborator
Oklahoma State University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy on selecting the target item on referent selection Children's choices on each trial of the task will be measured. Correct responses are those to the target (prompted) item - for referent selection, this is the item asked for in the prompt (e.g. shoe, dog) 1 minute
Primary Accuracy on selecting the target item on retention Children's choices on each trial of the task will be measured. Correct responses are those to the target (prompted) item - for retention, this is the item asked for in the prompt. 5 minutes
Primary Accuracy on selecting the target item on novel noun generalization task Children's choices on each trial of the task will be measured. Correct responses are those to the target (prompted) item - for generalization this will be considered as the shape-matching item (and not choosing a color or material match) 1 minute
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1